QuidelOrthoQDEL
About: QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Employees: 6,600
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 87
19% more call options, than puts
Call options by funds: $13.7M | Put options by funds: $11.6M
1.69% more ownership
Funds ownership: 108.95% [Q4 2024] → 110.64% (+1.69%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]
4% less funds holding
Funds holding: 272 [Q4 2024] → 260 (-12) [Q1 2025]
18% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 39
20% less capital invested
Capital invested by funds: $3.26B [Q4 2024] → $2.61B (-$658M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
UBS Lu Li | 1%downside $29 | Neutral Maintained | 8 May 2025 |
Jefferies Tycho Peterson | 50%upside $44 | Buy Upgraded | 8 May 2025 |
JP Morgan Casey Woodring | 15%downside $25 | Underweight Maintained | 21 Apr 2025 |
Financial journalist opinion
Based on 12 articles about QDEL published over the past 30 days









